Identification

Name
Brentuximab vedotin
Accession Number
DB08870
Type
Biotech
Groups
Approved, Investigational
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb) / Fusion proteins
Description

Brentuximab vedotin, also known as Adcetris®, is an antibody-drug conjugate that combines an anti-CD30 antibody with the drug monomethyl auristatin E (MMAE). It is an anti-neoplastic agent used in the treatment of Hodgkin's lymphoma and systemic anaplastic large cell lymphoma. Brentuximab vedotin was initially approved in 2011. In January 2012, the drug label was revised with a boxed warning of a condition known as progressive multifocal leukoencephalopathy and death due to opportunistic JC virus infection post treatment [5].

The U.S. Food and Drug Administration approved Adcetris in March 2018 to treat adult patients with previously untreated stage III or IV classical Hodgkin lymphoma (cHL) in combination with chemotherapy [5].

Adcetris has also been previously approved by the FDA to treat Hodgkin's lymphoma after relapse, Hodgkin's lymphoma after stem cell transplantation when a patient has a high risk of relapse or progression, systemic anaplastic large cell lymphoma (ALCL) after the failure of other treatment regimens, and primary cutaneous ALCL after failure of other treatment regimens [5].

Lymphoma is a malignancy that begins in the lymphatic system, which helps to combat infection and disease. Lymphoma may begin anywhere in the body and can spread to nearby lymph nodes. The two main types of lymphoma are Hodgkin lymphoma (also called Hodgkin disease) and non-Hodgkin lymphoma. Most individuals with Hodgkin's lymphoma have the classical type. In this type of lymphoma, large, abnormal lymphocytes (a type of white blood cell) are found in the lymph nodes called Reed-Sternberg cells. With early diagnosis and intervention, patients with Hodgkin lymphoma normally experience long-term remission [5].

The ECHELON-1 study results demonstrated superior efficacy of the drug combined with a chemotherapy regimen when it is compared to the previous standard of care. Importantly, removing the drug bleomycin, a highly toxic agent, was completely removed from the regimen. This demonstrates meaningful progress in treatment for patients affected by this disease [6].

Protein structure
Db08870
Protein chemical formula
C6476H9930N1690O2030S40
Protein average weight
150500.0 Da (range 149200-151800)
Sequences
Not Available
Synonyms
  • cAC10-vcMMAE
External IDs
SGN-35
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
AdcetrisPowder, for solution50 mgIntravenousSeattle Genetics, Inc.2013-02-19Not applicableCanada
AdcetrisInjection, powder, lyophilized, for solution50 mg/10.5mLIntravenousSeattle Genetics, Inc.2011-08-25Not applicableUs
AdcetrisInjection, powder, for solution50 mgIntravenousTakeda Pharma A/S2012-10-25Not applicableEu
Categories
UNII
7XL5ISS668
CAS number
914088-09-8

Pharmacology

Indication

Seattle Genetics Announced FDA Approval of ADCETRIS® (Brentuximab Vedotin) in combination with chemotherapy for adults with previously untreated stage III or IV Classical Hodgkin Lymphoma in March 2018 [5, 6].

Hodgkin lymphoma after failure of autologous stem cell transplant (ASCT) or after failure of at least two prior multi-agent chemotherapy regimens in patients who are not ASCT candidates [FDA Label], [5].

Systemic anaplastic large cell lymphoma after failure of at least one prior multi-agent chemotherapy regimen [FDA Label].

Structured Indications
Pharmacodynamics

Brentuximab vedotin causes apoptosis of tumor cells by preventing cell cycle progression of the G2 to M phase through disruption of the cytosolic microtuble network, thus preventing tumor growth and proliferation [FDA Label].

Hodgkin lymphoma (HL) is characterized by malignant Reed-Sternberg cells which express CD30, a marker of large cell lymphoma [4]. Until March 2018, USA National Comprehensive Cancer Network guidelines for patients with advanced HL (stage III/IV disease) recommend treatment with adriamycin, bleomycin, vinblastine, and dacarbazine (ABVD), or escalated bleomycin, etoposide, adriamycin, cyclophosphamide, vincristine, procarbazine, and prednisone (BEACOPP) as first-line regimens [7].

ABVD appears to be as effective, with fewer side effects, as escalated BEACOPP. Escalated BEACOPP leads to a greater progression-free survival but no difference in overall survival. Recent progress in technology has enabled a new shift to cancer therapy targeting specific molecules. Brentuximab vedotin, a CD30-directed antibody conjugate, selectively targets malignant HL cells [3].

The effect of Brentuximab vedotin (1.8 mg/kg) on the QTc interval was studied in an open-label, single-group study in 46 patients diagnosed with CD30-expressing hematologic malignancies. Ingestion of brentuximab vedotin did not prolong the mean cardiac QTc interval >10 ms from baseline levels. Smaller increases in the mean QTc interval (<10 ms) cannot be ruled out because this study did not include a placebo arm and a positive control arm [FDA Label].

Mechanism of action

Brentuximab vedotin is composed of 3 parts: a chimeric human-murine IgG1 that selectively targets CD30, monomethyl auristatin E (MMAE), which is a microtubule-disrupting agent, and a protease-susceptible linker that links the antibody and MMAE. The IgG1 antibody enables Brentuximab vedotin to target tumor cells expressing CD30 on their surface. Following this Brentuximab vedotin enters the cell. Once inside, the linker is cleaved releasing MMAE which binds disrupts the microtubule network [FDA Label].

The antibody component of this drug is a chimeric IgG1 directed against CD30. The small molecule, MMAE, is a microtubule-disrupting particle. MMAE is covalently attached to the antibody by a linker. Data suggest that the anticancer activity of Adcertris is due to the binding of the ADC to CD30-expressing cells, followed by internalization of the ADC-CD30 complex, and the subsequent release of MMAE by proteolytic cleavage. Binding of MMAE to tubulin disrupts the microtubule network within the cell, inducing cell cycle arrest and apoptotis of the malignant cells [FDA Label].

TargetActionsOrganism
ATumor necrosis factor receptor superfamily member 8
binder
Human
Absorption

Steady-state of the ADC is achieved within 21 days with every 3-week dosing of Adcetris. Minimal to no accumulation of ADC is observed with multiple doses at the every 3-week schedule. The time to maximum concentration for MMAE ranges from approximately 1 to 3 days. Similar to the ADC, steady-state of MMAE is achieved within 21 days with every 3-week dosing of Adcetris. MMAE exposures decrease with continued administration of Adcetris with about 50% to 80% of the exposure of the first dose being observed at future doses. The AUC of MMAE was measured to be approximately 2.2-fold higher in patients with hepatic impairment in comparison with patients with normal hepatic function [FDA Label].

Volume of distribution

MMAE is unlikely to displace or to be displaced by highly protein-bound drugs. In vitro studies show that MMAE is a substrate of P-gp and was not a potent inhibitor of P-gp [FDA Label].

Protein binding

In vitro, the binding of MMAE to human plasma proteins is in the range of 68–82% [FDA Label].

Metabolism

Data in both animals and humans suggest that only a small fraction of MMAE released from brentuximab vedotin is metabolized. In vitro data indicate that the MMAE metabolism that occurs is primarily via oxidation by CYP3A4/5. In vitro studies using human liver microsomes indicate that MMAE inhibits CYP3A4/5 but not other CYP isoforms. MMAE did not induce any major CYP450 enzymes in primary cultures of human hepatocytes [FDA Label].

Route of elimination

This drug appears follow metabolite kinetics, with the elimination of appearing to be limited by its rate of release from the antibody-drug conjugate (ADC). An excretion study was done in patients receiving a dose of 1.8 mg/kg of Adcetris. About 24% of the total MMAE ingested as part of the ADC during an ADCETRIS infusion was recovered in both urine and feces over a 7-day time frame. Of the recovered MMAE, approximately 72% was found in the feces and the majority of the excreted MMAE was excreted as unchanged drug [FDA Label].

Half life

The terminal half-life is approximately 4-6 days [FDA Label].

Clearance

The liver is the primary route of clearance for MMAE. The pharmacokinetics and safety of Brentuximab vedotin and MMAE were examined after the administration of 1.2 mg/kg of Adcetris to patients with mild, moderate, and severe hepatic impairment. In patients with moderate and severe hepatic impairment, the rate of ≥Grade 3 adverse reactions was 6/6 (100%) compared to 3/8 (38%) in patients with normal hepatic function [FDA Label]. It is recommended to avoid use in patients with severe renal impairment (CrCl <30mL/min) [9].

Toxicity

The most severe toxic reaction seen in patients is progressive multifocal leukoencephalopathy [FDA Label].

Progressive multifocal leukoencephalopathy (PML) follows infection by the JC virus (which is not related to Creutzfeldt-Jakob disease). Symptoms of this condition begin insidiously and usually worsen progressively. The symptoms vary depending on which region of the brain is infected. In about two out of three patients, mental function deteriorates rapidly, leading to dementia. Speaking and walking may become increasingly difficult. Vision may be impaired, and total blindness may occur. Rarely, headaches and seizures can occur, mainly in immunocompromised patients. The most serious sequela of this condition is death [10].

Common adverse effects of Adcetris may include: neutropenia, anemia, peripheral neuropathy, nausea, fatigue, constipation, diarrhea, vomiting, and fever. In one trial, neutropenia occurred in 91 percent of patients treated with Adcetris plus chemotherapy, which was associated with a 19 percent rate of febrile neutropenia (neutropenia and fever) [5]. Preventive treatment with G-CSF, a growth factor for the bone marrow to produce white blood cells, is recommended with Adcetris plus chemotherapy for the first-line treatment of Stage III or IV cHL [5].

Adcetris has a boxed warning that emphasizes the risk of John Cunningham virus infection leading to progressive multifocal leukoencephalopathy, or PML, a rare but serious brain infection that may be lethal.

Serious risks of Adcetris include peripheral neuropathy; severe allergic (anaphylaxis) or infusion-site reactions; damage to the blood, lungs and liver (hematologic, pulmonary and hepato-toxicities); severe/opportunistic infections; metabolic abnormalities (tumor lysis syndrome); dermatologic reactions and gastrointestinal complications. Adcetris may cause harm to the fetus and newborn baby; women should be warned of the potential risk to the fetus and to use effective contraception, and to avoid breastfeeding while taking Adcetris [5].

MMAE was found to be genotoxic in the rat bone marrow micronucleus study through an aneugenic mechanism. This effect is consistent with the pharmacological effect of MMAE as a microtubule-disrupting drug. Fertility studies with Brentuximab vedotin or MMAE have not been conducted. Despite this, results of repeat-dose toxicity studies in rats suggest the potential for Brentuximab vedotin to have a negative effect on male reproductive function and fertility. In a 4-week repeated-dose toxicity study in rats with weekly dosing at 0.5, 5 or 10 mg/kg brentuximab vedotin, seminiferous tubule degeneration, Sertoli cell vacuolation, reduced spermatogenesis, and aspermia were observed [5]. Effects in animals were seen mostly at 5 and 10 mg/kg doses of brentuximab vedotin. These dosages are approximately 3 and 6-fold the human recommended dose of 1.8 mg/kg, respectively, based on individual body weight [FDA Label].

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
AbemaciclibThe serum concentration of Brentuximab vedotin can be increased when it is combined with Abemaciclib.Approved, Investigational
AcetaminophenThe serum concentration of Brentuximab vedotin can be increased when it is combined with Acetaminophen.Approved
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of Brentuximab vedotin.Approved
AcetyldigoxinAcetyldigoxin may decrease the cardiotoxic activities of Brentuximab vedotin.Experimental
AfatinibThe serum concentration of Brentuximab vedotin can be increased when it is combined with Afatinib.Approved
AlbendazoleThe serum concentration of Brentuximab vedotin can be increased when it is combined with Albendazole.Approved, Vet Approved
AldosteroneThe serum concentration of Brentuximab vedotin can be decreased when it is combined with Aldosterone.Experimental, Investigational
AlectinibThe serum concentration of Brentuximab vedotin can be increased when it is combined with Alectinib.Approved, Investigational
AlfentanilThe serum concentration of Brentuximab vedotin can be increased when it is combined with Alfentanil.Approved, Illicit
AmantadineThe serum concentration of Brentuximab vedotin can be increased when it is combined with Amantadine.Approved
Aminohippuric acidThe serum concentration of Brentuximab vedotin can be increased when it is combined with Aminohippuric acid.Approved, Investigational
AmiodaroneThe serum concentration of Brentuximab vedotin can be increased when it is combined with Amiodarone.Approved, Investigational
AmitriptylineThe serum concentration of Brentuximab vedotin can be increased when it is combined with Amitriptyline.Approved
AmlodipineThe serum concentration of Brentuximab vedotin can be increased when it is combined with Amlodipine.Approved
AmprenavirThe serum concentration of Brentuximab vedotin can be decreased when it is combined with Amprenavir.Approved, Investigational
AmsacrineThe serum concentration of Brentuximab vedotin can be increased when it is combined with Amsacrine.Approved, Investigational
AncestimThe risk or severity of cytotoxicity can be increased when Ancestim is combined with Brentuximab vedotin.Approved, Investigational, Withdrawn
Anthrax immune globulin humanThe risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Anthrax immune globulin human.Approved
ApalutamideThe serum concentration of Brentuximab vedotin can be decreased when it is combined with Apalutamide.Approved, Investigational
AprepitantThe serum concentration of Brentuximab vedotin can be increased when it is combined with Aprepitant.Approved, Investigational
AstemizoleThe serum concentration of Brentuximab vedotin can be increased when it is combined with Astemizole.Approved, Withdrawn
AsunaprevirThe serum concentration of Asunaprevir can be increased when it is combined with Brentuximab vedotin.Approved, Investigational, Withdrawn
AtazanavirThe serum concentration of Brentuximab vedotin can be increased when it is combined with Atazanavir.Approved, Investigational
AtenololThe serum concentration of Brentuximab vedotin can be increased when it is combined with Atenolol.Approved
AtomoxetineThe metabolism of Brentuximab vedotin can be decreased when combined with Atomoxetine.Approved
AtorvastatinThe risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Atorvastatin.Approved
AzelastineThe serum concentration of Brentuximab vedotin can be increased when it is combined with Azelastine.Approved
AzithromycinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Azithromycin.Approved
Bacillus calmette-guerin substrain connaught live antigenThe risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Bacillus calmette-guerin substrain connaught live antigen.Approved, Investigational
Bacillus calmette-guerin substrain tice live antigenThe risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Bacillus calmette-guerin substrain tice live antigen.Approved
BCG vaccineThe therapeutic efficacy of BCG vaccine can be decreased when used in combination with Brentuximab vedotin.Investigational
BelimumabThe risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Belimumab.Approved
BenzocaineThe serum concentration of Brentuximab vedotin can be increased when it is combined with Benzocaine.Approved, Investigational
BepridilThe serum concentration of Brentuximab vedotin can be increased when it is combined with Bepridil.Approved, Withdrawn
BevacizumabBevacizumab may increase the cardiotoxic activities of Brentuximab vedotin.Approved, Investigational
BiperidenThe serum concentration of Brentuximab vedotin can be increased when it is combined with Biperiden.Approved, Investigational
BleomycinThe risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Bleomycin.Approved, Investigational
BoceprevirThe serum concentration of Brentuximab vedotin can be increased when it is combined with Boceprevir.Approved, Withdrawn
BortezomibThe metabolism of Brentuximab vedotin can be decreased when combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Brentuximab vedotin can be decreased when it is combined with Bosentan.Approved, Investigational
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Brentuximab vedotin.Approved
BromocriptineThe serum concentration of Brentuximab vedotin can be increased when it is combined with Bromocriptine.Approved, Investigational
BuprenorphineThe serum concentration of Brentuximab vedotin can be increased when it is combined with Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BuspironeThe serum concentration of Brentuximab vedotin can be increased when it is combined with Buspirone.Approved, Investigational
CabazitaxelThe serum concentration of Brentuximab vedotin can be increased when it is combined with Cabazitaxel.Approved
CabergolineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Brentuximab vedotin.Approved
CaffeineThe serum concentration of Brentuximab vedotin can be increased when it is combined with Caffeine.Approved
CanagliflozinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Canagliflozin.Approved
CandesartanThe serum concentration of Brentuximab vedotin can be increased when it is combined with Candesartan.Experimental
Candesartan cilexetilThe serum concentration of Brentuximab vedotin can be increased when it is combined with Candesartan cilexetil.Approved
CaptoprilThe serum concentration of Brentuximab vedotin can be increased when it is combined with Captopril.Approved
CarbamazepineThe serum concentration of Brentuximab vedotin can be decreased when it is combined with Carbamazepine.Approved, Investigational
CarvedilolThe serum concentration of Brentuximab vedotin can be increased when it is combined with Carvedilol.Approved, Investigational
CaspofunginThe serum concentration of Brentuximab vedotin can be increased when it is combined with Caspofungin.Approved
CeritinibThe serum concentration of Brentuximab vedotin can be increased when it is combined with Ceritinib.Approved
CerivastatinThe serum concentration of Cerivastatin can be increased when it is combined with Brentuximab vedotin.Approved, Withdrawn
ChloroquineThe serum concentration of Brentuximab vedotin can be increased when it is combined with Chloroquine.Approved, Investigational, Vet Approved
ChlorpromazineThe serum concentration of Brentuximab vedotin can be increased when it is combined with Chlorpromazine.Approved, Investigational, Vet Approved
ChlorpropamideThe serum concentration of Brentuximab vedotin can be increased when it is combined with Chlorpropamide.Approved, Investigational
ChlorprothixeneThe serum concentration of Brentuximab vedotin can be increased when it is combined with Chlorprothixene.Approved, Investigational, Withdrawn
CholesterolThe serum concentration of Brentuximab vedotin can be increased when it is combined with Cholesterol.Approved, Experimental, Investigational
Cholic AcidThe serum concentration of Brentuximab vedotin can be decreased when it is combined with Cholic Acid.Approved
CilazaprilThe serum concentration of Brentuximab vedotin can be increased when it is combined with Cilazapril.Approved
CimetidineThe serum concentration of Brentuximab vedotin can be decreased when it is combined with Cimetidine.Approved, Investigational
CiprofloxacinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Ciprofloxacin.Approved, Investigational
CitalopramThe serum concentration of Brentuximab vedotin can be increased when it is combined with Citalopram.Approved
ClarithromycinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Clarithromycin.Approved
ClemastineThe metabolism of Brentuximab vedotin can be decreased when combined with Clemastine.Approved, Investigational
ClofazimineThe serum concentration of Brentuximab vedotin can be increased when it is combined with Clofazimine.Approved, Investigational
ClomipramineThe serum concentration of Brentuximab vedotin can be increased when it is combined with Clomipramine.Approved, Investigational, Vet Approved
Clostridium tetani toxoid antigen (formaldehyde inactivated)The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated).Approved
ClotrimazoleThe serum concentration of Brentuximab vedotin can be decreased when it is combined with Clotrimazole.Approved, Vet Approved
CobicistatThe serum concentration of Brentuximab vedotin can be increased when it is combined with Cobicistat.Approved
ColchicineThe serum concentration of Brentuximab vedotin can be increased when it is combined with Colchicine.Approved
ColforsinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Colforsin.Experimental, Investigational
ConivaptanThe serum concentration of Conivaptan can be increased when it is combined with Brentuximab vedotin.Approved, Investigational
Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated)The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated).Approved
CrizotinibThe serum concentration of Brentuximab vedotin can be increased when it is combined with Crizotinib.Approved
CyclophosphamideCyclophosphamide may increase the cardiotoxic activities of Brentuximab vedotin.Approved, Investigational
CyclosporineThe serum concentration of Brentuximab vedotin can be decreased when it is combined with Cyclosporine.Approved, Investigational, Vet Approved
CymarinCymarin may decrease the cardiotoxic activities of Brentuximab vedotin.Experimental
DabrafenibThe serum concentration of Brentuximab vedotin can be decreased when it is combined with Dabrafenib.Approved, Investigational
DaclatasvirThe serum concentration of Brentuximab vedotin can be increased when it is combined with Daclatasvir.Approved, Investigational
DactinomycinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Dactinomycin.Approved, Investigational
DarunavirThe serum concentration of Brentuximab vedotin can be increased when it is combined with Darunavir.Approved
DasatinibThe serum concentration of Brentuximab vedotin can be increased when it is combined with Dasatinib.Approved, Investigational
DaunorubicinThe serum concentration of Brentuximab vedotin can be decreased when it is combined with Daunorubicin.Approved
DeferasiroxThe serum concentration of Brentuximab vedotin can be decreased when it is combined with Deferasirox.Approved, Investigational
DelavirdineThe metabolism of Brentuximab vedotin can be decreased when combined with Delavirdine.Approved
DenosumabThe risk or severity of adverse effects can be increased when Denosumab is combined with Brentuximab vedotin.Approved
DesipramineThe serum concentration of Brentuximab vedotin can be increased when it is combined with Desipramine.Approved, Investigational
DeslanosideDeslanoside may decrease the cardiotoxic activities of Brentuximab vedotin.Approved
DesloratadineThe serum concentration of Brentuximab vedotin can be increased when it is combined with Desloratadine.Approved, Investigational
DexamethasoneThe serum concentration of Brentuximab vedotin can be decreased when it is combined with Dexamethasone.Approved, Investigational, Vet Approved
DextromethorphanThe serum concentration of Brentuximab vedotin can be increased when it is combined with Dextromethorphan.Approved
DiclofenacThe serum concentration of Brentuximab vedotin can be increased when it is combined with Diclofenac.Approved, Vet Approved
DigitoxinDigitoxin may decrease the cardiotoxic activities of Brentuximab vedotin.Approved, Investigational
DigoxinThe serum concentration of Brentuximab vedotin can be decreased when it is combined with Digoxin.Approved
Digoxin Immune Fab (Ovine)Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Brentuximab vedotin.Approved
DihydroergocornineThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Brentuximab vedotin.Approved
DihydroergocristineThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Brentuximab vedotin.Approved, Experimental
DihydroergocryptineThe risk or severity of adverse effects can be increased when Dihydroergocryptine is combined with Brentuximab vedotin.Experimental
DihydroergotamineThe serum concentration of Brentuximab vedotin can be increased when it is combined with Dihydroergotamine.Approved, Investigational
DiltiazemThe serum concentration of Brentuximab vedotin can be increased when it is combined with Diltiazem.Approved, Investigational
DipyridamoleThe serum concentration of Brentuximab vedotin can be increased when it is combined with Dipyridamole.Approved
DocetaxelThe risk or severity of adverse effects can be increased when Docetaxel is combined with Brentuximab vedotin.Approved, Investigational
DoxazosinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Doxazosin.Approved
DoxepinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Doxepin.Approved, Investigational
DoxorubicinThe serum concentration of Brentuximab vedotin can be decreased when it is combined with Doxorubicin.Approved, Investigational
DoxycyclineThe metabolism of Brentuximab vedotin can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DronabinolThe serum concentration of Brentuximab vedotin can be increased when it is combined with Dronabinol.Approved, Illicit
DronedaroneThe serum concentration of Brentuximab vedotin can be increased when it is combined with Dronedarone.Approved
EnalaprilThe serum concentration of Brentuximab vedotin can be increased when it is combined with Enalapril.Approved, Vet Approved
EnasidenibThe serum concentration of Brentuximab vedotin can be increased when it is combined with Enasidenib.Approved, Investigational
EnzalutamideThe serum concentration of Brentuximab vedotin can be decreased when it is combined with Enzalutamide.Approved
ErgonovineThe serum concentration of Brentuximab vedotin can be increased when it is combined with Ergonovine.Approved
ErgotamineThe serum concentration of Brentuximab vedotin can be increased when it is combined with Ergotamine.Approved
ErythromycinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Erythromycin.Approved, Investigational, Vet Approved
EstramustineThe serum concentration of Brentuximab vedotin can be increased when it is combined with Estramustine.Approved, Investigational
EstriolThe serum concentration of Brentuximab vedotin can be decreased when it is combined with Estriol.Approved, Investigational, Vet Approved
EstroneThe serum concentration of Brentuximab vedotin can be decreased when it is combined with Estrone.Approved
EtoposideThe serum concentration of Brentuximab vedotin can be increased when it is combined with Etoposide.Approved
EtravirineThe serum concentration of Brentuximab vedotin can be increased when it is combined with Etravirine.Approved
FelodipineThe serum concentration of Brentuximab vedotin can be increased when it is combined with Felodipine.Approved, Investigational
FentanylThe serum concentration of Brentuximab vedotin can be increased when it is combined with Fentanyl.Approved, Illicit, Investigational, Vet Approved
FexofenadineThe serum concentration of Brentuximab vedotin can be increased when it is combined with Fexofenadine.Approved, Investigational
FidaxomicinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Fidaxomicin.Approved
FingolimodBrentuximab vedotin may increase the immunosuppressive activities of Fingolimod.Approved, Investigational
FluconazoleThe serum concentration of Brentuximab vedotin can be increased when it is combined with Fluconazole.Approved, Investigational
FluoxetineThe serum concentration of Brentuximab vedotin can be increased when it is combined with Fluoxetine.Approved, Vet Approved
FlupentixolThe serum concentration of Brentuximab vedotin can be increased when it is combined with Flupentixol.Approved, Investigational, Withdrawn
FluphenazineThe serum concentration of Brentuximab vedotin can be increased when it is combined with Fluphenazine.Approved
FlurazepamThe serum concentration of Brentuximab vedotin can be increased when it is combined with Flurazepam.Approved, Illicit, Investigational
FluvastatinThe serum concentration of Fluvastatin can be increased when it is combined with Brentuximab vedotin.Approved
FluvoxamineThe serum concentration of Brentuximab vedotin can be increased when it is combined with Fluvoxamine.Approved, Investigational
FosamprenavirThe metabolism of Brentuximab vedotin can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Brentuximab vedotin can be increased when it is combined with Fosaprepitant.Approved
FosphenytoinThe serum concentration of Brentuximab vedotin can be decreased when it is combined with Fosphenytoin.Approved, Investigational
Fusidic AcidThe serum concentration of Brentuximab vedotin can be increased when it is combined with Fusidic Acid.Approved, Investigational
G17DTThe risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with G17DT.Investigational
GefitinibThe serum concentration of Brentuximab vedotin can be increased when it is combined with Gefitinib.Approved, Investigational
GenisteinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Genistein.Investigational
GI-5005The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with GI-5005.Investigational
GitoformateGitoformate may decrease the cardiotoxic activities of Brentuximab vedotin.Experimental
GlecaprevirThe serum concentration of Brentuximab vedotin can be increased when it is combined with Glecaprevir.Approved, Investigational
GlyburideThe serum concentration of Brentuximab vedotin can be increased when it is combined with Glyburide.Approved
GlycerinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Glycerin.Approved, Investigational
Gramicidin DThe serum concentration of Brentuximab vedotin can be increased when it is combined with Gramicidin D.Approved
GrepafloxacinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Grepafloxacin.Approved, Investigational, Withdrawn
HaloperidolThe serum concentration of Brentuximab vedotin can be increased when it is combined with Haloperidol.Approved
Hepatitis A VaccineThe risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Hepatitis A Vaccine.Approved
Hepatitis B Vaccine (Recombinant)The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Hepatitis B Vaccine (Recombinant).Approved, Withdrawn
Human rabies virus immune globulinThe risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Human rabies virus immune globulin.Approved
HydrocortisoneThe serum concentration of Brentuximab vedotin can be increased when it is combined with Hydrocortisone.Approved, Vet Approved
IbrutinibThe serum concentration of Ibrutinib can be increased when it is combined with Brentuximab vedotin.Approved
IdelalisibThe serum concentration of Brentuximab vedotin can be increased when it is combined with Idelalisib.Approved
ImatinibThe serum concentration of Brentuximab vedotin can be increased when it is combined with Imatinib.Approved
ImipramineThe serum concentration of Brentuximab vedotin can be increased when it is combined with Imipramine.Approved
IndinavirThe serum concentration of Brentuximab vedotin can be increased when it is combined with Indinavir.Approved
IndomethacinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Indomethacin.Approved, Investigational
INGN 201The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with INGN 201.Investigational
INGN 225The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with INGN 225.Investigational
IsavuconazoleThe serum concentration of Brentuximab vedotin can be increased when it is combined with Isavuconazole.Approved, Investigational
IsavuconazoniumThe serum concentration of Brentuximab vedotin can be increased when it is combined with Isavuconazonium.Approved, Investigational
IsradipineThe metabolism of Brentuximab vedotin can be decreased when combined with Isradipine.Approved, Investigational
ItraconazoleThe serum concentration of Brentuximab vedotin can be increased when it is combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Brentuximab vedotin can be increased when it is combined with Ivacaftor.Approved
IvermectinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Ivermectin.Approved, Investigational, Vet Approved
Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated)The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated).Approved
KetamineThe serum concentration of Brentuximab vedotin can be increased when it is combined with Ketamine.Approved, Vet Approved
KetoconazoleThe serum concentration of Brentuximab vedotin can be increased when it is combined with Ketoconazole.Approved, Investigational
Lanatoside CLanatoside C may decrease the cardiotoxic activities of Brentuximab vedotin.Experimental
LansoprazoleThe serum concentration of Brentuximab vedotin can be increased when it is combined with Lansoprazole.Approved, Investigational
LapatinibThe serum concentration of Brentuximab vedotin can be increased when it is combined with Lapatinib.Approved, Investigational
LeflunomideThe risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Leflunomide.Approved, Investigational
LetermovirThe serum concentration of Brentuximab vedotin can be increased when it is combined with Letermovir.Approved, Investigational
LevofloxacinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Levofloxacin.Approved, Investigational
LevothyroxineThe serum concentration of Brentuximab vedotin can be decreased when it is combined with Levothyroxine.Approved
LidocaineThe serum concentration of Brentuximab vedotin can be increased when it is combined with Lidocaine.Approved, Vet Approved
LiothyronineThe serum concentration of Brentuximab vedotin can be decreased when it is combined with Liothyronine.Approved, Vet Approved
LiotrixThe serum concentration of Brentuximab vedotin can be decreased when it is combined with Liotrix.Approved
LisurideThe risk or severity of adverse effects can be increased when Lisuride is combined with Brentuximab vedotin.Approved, Investigational
LomitapideThe serum concentration of Brentuximab vedotin can be increased when it is combined with Lomitapide.Approved, Investigational
LoperamideThe serum concentration of Brentuximab vedotin can be increased when it is combined with Loperamide.Approved
LopinavirThe serum concentration of Brentuximab vedotin can be increased when it is combined with Lopinavir.Approved
LoratadineThe serum concentration of Brentuximab vedotin can be increased when it is combined with Loratadine.Approved, Investigational
LorpiprazoleThe serum concentration of Brentuximab vedotin can be increased when it is combined with Lorpiprazole.Approved
LosartanThe serum concentration of Brentuximab vedotin can be increased when it is combined with Losartan.Approved
LovastatinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Lovastatin.Approved, Investigational
LuliconazoleThe serum concentration of Brentuximab vedotin can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Brentuximab vedotin can be decreased when it is combined with Lumacaftor.Approved
Lysergic Acid DiethylamideThe risk or severity of adverse effects can be increased when Lysergic Acid Diethylamide is combined with Brentuximab vedotin.Illicit, Investigational, Withdrawn
MaprotilineThe serum concentration of Brentuximab vedotin can be increased when it is combined with Maprotiline.Approved, Investigational
MebendazoleThe serum concentration of Brentuximab vedotin can be increased when it is combined with Mebendazole.Approved, Vet Approved
MefloquineThe serum concentration of Brentuximab vedotin can be increased when it is combined with Mefloquine.Approved, Investigational
Megestrol acetateThe serum concentration of Brentuximab vedotin can be increased when it is combined with Megestrol acetate.Approved, Investigational, Vet Approved
MeprobamateThe serum concentration of Brentuximab vedotin can be increased when it is combined with Meprobamate.Approved, Illicit
MetergolineThe risk or severity of adverse effects can be increased when Metergoline is combined with Brentuximab vedotin.Experimental
MethadoneThe serum concentration of Brentuximab vedotin can be increased when it is combined with Methadone.Approved
MethylergometrineThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Brentuximab vedotin.Approved
MethysergideThe risk or severity of adverse effects can be increased when Methysergide is combined with Brentuximab vedotin.Approved
MetildigoxinMetildigoxin may decrease the cardiotoxic activities of Brentuximab vedotin.Experimental
MetoprololThe serum concentration of Brentuximab vedotin can be increased when it is combined with Metoprolol.Approved, Investigational
MevastatinThe serum concentration of Mevastatin can be increased when it is combined with Brentuximab vedotin.Experimental
MibefradilThe serum concentration of Brentuximab vedotin can be increased when it is combined with Mibefradil.Investigational, Withdrawn
MiconazoleThe serum concentration of Brentuximab vedotin can be increased when it is combined with Miconazole.Approved, Investigational, Vet Approved
MidazolamThe serum concentration of Brentuximab vedotin can be decreased when it is combined with Midazolam.Approved, Illicit
MifepristoneThe serum concentration of Brentuximab vedotin can be increased when it is combined with Mifepristone.Approved, Investigational
MitomycinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Mitomycin.Approved
MitotaneThe serum concentration of Brentuximab vedotin can be decreased when it is combined with Mitotane.Approved
MitoxantroneThe serum concentration of Brentuximab vedotin can be decreased when it is combined with Mitoxantrone.Approved, Investigational
MorphineThe serum concentration of Brentuximab vedotin can be increased when it is combined with Morphine.Approved, Investigational
NaltrexoneThe serum concentration of Brentuximab vedotin can be increased when it is combined with Naltrexone.Approved, Investigational, Vet Approved
NaringeninThe serum concentration of Brentuximab vedotin can be increased when it is combined with Naringenin.Experimental
NatalizumabThe risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Natalizumab.Approved, Investigational
NefazodoneThe serum concentration of Brentuximab vedotin can be increased when it is combined with Nefazodone.Approved, Withdrawn
NelfinavirThe serum concentration of Brentuximab vedotin can be increased when it is combined with Nelfinavir.Approved
NeostigmineThe serum concentration of Brentuximab vedotin can be increased when it is combined with Neostigmine.Approved, Vet Approved
NetupitantThe serum concentration of Brentuximab vedotin can be increased when it is combined with Netupitant.Approved, Investigational
NevirapineThe serum concentration of Brentuximab vedotin can be decreased when it is combined with Nevirapine.Approved
NicardipineThe serum concentration of Brentuximab vedotin can be increased when it is combined with Nicardipine.Approved, Investigational
NicergolineThe risk or severity of adverse effects can be increased when Nicergoline is combined with Brentuximab vedotin.Approved, Investigational
NifedipineThe serum concentration of Brentuximab vedotin can be decreased when it is combined with Nifedipine.Approved
NilotinibThe serum concentration of Brentuximab vedotin can be increased when it is combined with Nilotinib.Approved, Investigational
NisoldipineThe serum concentration of Brentuximab vedotin can be increased when it is combined with Nisoldipine.Approved
NitrazepamThe serum concentration of Brentuximab vedotin can be increased when it is combined with Nitrazepam.Approved
NitrendipineThe serum concentration of Brentuximab vedotin can be increased when it is combined with Nitrendipine.Approved, Investigational
NorethisteroneThe serum concentration of Brentuximab vedotin can be decreased when it is combined with Norethisterone.Approved
OcrelizumabOcrelizumab may increase the immunosuppressive activities of Brentuximab vedotin.Approved, Investigational
OlaparibThe metabolism of Brentuximab vedotin can be decreased when combined with Olaparib.Approved
OleandrinOleandrin may decrease the cardiotoxic activities of Brentuximab vedotin.Experimental, Investigational
OmeprazoleThe serum concentration of Brentuximab vedotin can be increased when it is combined with Omeprazole.Approved, Investigational, Vet Approved
OsimertinibThe serum concentration of Brentuximab vedotin can be increased when it is combined with Osimertinib.Approved
OuabainOuabain may decrease the cardiotoxic activities of Brentuximab vedotin.Approved
P-NitrophenolThe serum concentration of Brentuximab vedotin can be increased when it is combined with P-Nitrophenol.Experimental
PaclitaxelThe serum concentration of Brentuximab vedotin can be increased when it is combined with Paclitaxel.Approved, Vet Approved
PalbociclibThe serum concentration of Brentuximab vedotin can be increased when it is combined with Palbociclib.Approved, Investigational
Palmitic AcidThe serum concentration of Brentuximab vedotin can be increased when it is combined with Palmitic Acid.Approved, Experimental
PantoprazoleThe serum concentration of Brentuximab vedotin can be increased when it is combined with Pantoprazole.Approved
ParoxetineThe serum concentration of Brentuximab vedotin can be increased when it is combined with Paroxetine.Approved, Investigational
PentobarbitalThe serum concentration of Brentuximab vedotin can be decreased when it is combined with Pentobarbital.Approved, Investigational, Vet Approved
PergolideThe risk or severity of adverse effects can be increased when Pergolide is combined with Brentuximab vedotin.Approved, Investigational, Vet Approved, Withdrawn
PerindoprilThe serum concentration of Brentuximab vedotin can be increased when it is combined with Perindopril.Approved
PeruvosidePeruvoside may decrease the cardiotoxic activities of Brentuximab vedotin.Experimental
PhenobarbitalThe serum concentration of Brentuximab vedotin can be decreased when it is combined with Phenobarbital.Approved, Investigational
PhenytoinThe serum concentration of Brentuximab vedotin can be decreased when it is combined with Phenytoin.Approved, Vet Approved
PibrentasvirThe serum concentration of Brentuximab vedotin can be increased when it is combined with Pibrentasvir.Approved, Investigational
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Brentuximab vedotin.Approved, Investigational
PimozideThe serum concentration of Brentuximab vedotin can be increased when it is combined with Pimozide.Approved
PitavastatinThe serum concentration of Pitavastatin can be increased when it is combined with Brentuximab vedotin.Approved
PitolisantThe serum concentration of Brentuximab vedotin can be decreased when it is combined with Pitolisant.Approved, Investigational
Platelet Activating FactorThe serum concentration of Brentuximab vedotin can be decreased when it is combined with Platelet Activating Factor.Experimental
PonatinibThe serum concentration of Brentuximab vedotin can be increased when it is combined with Ponatinib.Approved, Investigational
PosaconazoleThe serum concentration of Brentuximab vedotin can be increased when it is combined with Posaconazole.Approved, Investigational, Vet Approved
PravastatinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Pravastatin.Approved
PrazosinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Prazosin.Approved
PrednisoneThe serum concentration of Brentuximab vedotin can be increased when it is combined with Prednisone.Approved, Vet Approved
PrimidoneThe serum concentration of Brentuximab vedotin can be decreased when it is combined with Primidone.Approved, Vet Approved
ProbenecidThe serum concentration of Brentuximab vedotin can be increased when it is combined with Probenecid.Approved, Investigational
ProgesteroneThe serum concentration of Brentuximab vedotin can be decreased when it is combined with Progesterone.Approved, Vet Approved
PromethazineThe serum concentration of Brentuximab vedotin can be increased when it is combined with Promethazine.Approved, Investigational
PropafenoneThe serum concentration of Brentuximab vedotin can be increased when it is combined with Propafenone.Approved
PropranololThe serum concentration of Brentuximab vedotin can be increased when it is combined with Propranolol.Approved, Investigational
ProscillaridinProscillaridin may decrease the cardiotoxic activities of Brentuximab vedotin.Experimental
ProtriptylineThe serum concentration of Brentuximab vedotin can be increased when it is combined with Protriptyline.Approved
QuercetinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Quercetin.Experimental, Investigational
QuinacrineThe serum concentration of Brentuximab vedotin can be increased when it is combined with Quinacrine.Approved, Investigational
QuinidineThe serum concentration of Brentuximab vedotin can be increased when it is combined with Quinidine.Approved, Investigational
QuinineThe serum concentration of Brentuximab vedotin can be increased when it is combined with Quinine.Approved
Rabies virus inactivated antigen, AThe risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Rabies virus inactivated antigen, A.Approved, Investigational
Rabies virus inactivated antigen, AThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Brentuximab vedotin.Approved, Investigational
RanitidineThe serum concentration of Brentuximab vedotin can be increased when it is combined with Ranitidine.Approved
RanolazineThe metabolism of Brentuximab vedotin can be decreased when combined with Ranolazine.Approved, Investigational
ReboxetineThe serum concentration of Brentuximab vedotin can be increased when it is combined with Reboxetine.Approved, Investigational
RegorafenibThe serum concentration of Brentuximab vedotin can be increased when it is combined with Regorafenib.Approved
ReserpineThe serum concentration of Brentuximab vedotin can be decreased when it is combined with Reserpine.Approved, Investigational
RifabutinThe serum concentration of Brentuximab vedotin can be decreased when it is combined with Rifabutin.Approved, Investigational
RifampicinThe serum concentration of Brentuximab vedotin can be decreased when it is combined with Rifampicin.Approved
RifapentineThe serum concentration of Brentuximab vedotin can be decreased when it is combined with Rifapentine.Approved, Investigational
RilpivirineThe serum concentration of Brentuximab vedotin can be increased when it is combined with Rilpivirine.Approved
RindopepimutThe risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Rindopepimut.Investigational
RitonavirThe serum concentration of Brentuximab vedotin can be decreased when it is combined with Ritonavir.Approved, Investigational
RoflumilastRoflumilast may increase the immunosuppressive activities of Brentuximab vedotin.Approved
RolapitantThe serum concentration of Brentuximab vedotin can be increased when it is combined with Rolapitant.Approved, Investigational
RosuvastatinThe serum concentration of Rosuvastatin can be increased when it is combined with Brentuximab vedotin.Approved
Rotavirus VaccineThe risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Rotavirus Vaccine.Approved
Rubella virus vaccineThe risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Rubella virus vaccine.Approved, Investigational
RucaparibThe serum concentration of Brentuximab vedotin can be increased when it is combined with Rucaparib.Approved, Investigational
Salmonella typhi ty2 vi polysaccharide antigenThe risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Salmonella typhi ty2 vi polysaccharide antigen.Approved
Salmonella typhi ty21a live antigenThe risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Salmonella typhi ty21a live antigen.Approved
SaquinavirThe serum concentration of Brentuximab vedotin can be increased when it is combined with Saquinavir.Approved, Investigational
SarilumabThe therapeutic efficacy of Brentuximab vedotin can be decreased when used in combination with Sarilumab.Approved, Investigational
ScopolamineThe serum concentration of Brentuximab vedotin can be increased when it is combined with Scopolamine.Approved, Investigational
SelegilineThe serum concentration of Brentuximab vedotin can be increased when it is combined with Selegiline.Approved, Investigational, Vet Approved
SertralineThe serum concentration of Brentuximab vedotin can be increased when it is combined with Sertraline.Approved
SildenafilThe metabolism of Brentuximab vedotin can be decreased when combined with Sildenafil.Approved, Investigational
SiltuximabThe serum concentration of Brentuximab vedotin can be decreased when it is combined with Siltuximab.Approved, Investigational
SimeprevirThe serum concentration of Brentuximab vedotin can be increased when it is combined with Simeprevir.Approved
SimvastatinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Simvastatin.Approved
Sipuleucel-TThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Brentuximab vedotin.Approved, Investigational
SirolimusThe serum concentration of Brentuximab vedotin can be decreased when it is combined with Sirolimus.Approved, Investigational
SorafenibThe serum concentration of Brentuximab vedotin can be increased when it is combined with Sorafenib.Approved, Investigational
SpironolactoneThe serum concentration of Brentuximab vedotin can be increased when it is combined with Spironolactone.Approved
SRP 299The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with SRP 299.Investigational
St. John's WortThe serum concentration of Brentuximab vedotin can be decreased when it is combined with St. John's Wort.Approved, Investigational, Nutraceutical
StaurosporineThe serum concentration of Brentuximab vedotin can be increased when it is combined with Staurosporine.Experimental
StiripentolThe serum concentration of Brentuximab vedotin can be increased when it is combined with Stiripentol.Approved
StreptozocinThe serum concentration of Brentuximab vedotin can be decreased when it is combined with Streptozocin.Approved, Investigational
SulfinpyrazoneThe serum concentration of Brentuximab vedotin can be increased when it is combined with Sulfinpyrazone.Approved
SulfisoxazoleThe metabolism of Brentuximab vedotin can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
SumatriptanThe serum concentration of Brentuximab vedotin can be increased when it is combined with Sumatriptan.Approved, Investigational
SunitinibThe serum concentration of Brentuximab vedotin can be increased when it is combined with Sunitinib.Approved, Investigational
TacrineThe serum concentration of Brentuximab vedotin can be increased when it is combined with Tacrine.Investigational, Withdrawn
TacrolimusTacrolimus may increase the immunosuppressive activities of Brentuximab vedotin.Approved, Investigational
TamoxifenThe serum concentration of Brentuximab vedotin can be decreased when it is combined with Tamoxifen.Approved
Taurocholic AcidThe serum concentration of Brentuximab vedotin can be increased when it is combined with Taurocholic Acid.Experimental
TecemotideThe risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Tecemotide.Investigational
TelaprevirThe serum concentration of Brentuximab vedotin can be increased when it is combined with Telaprevir.Approved, Withdrawn
TelithromycinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Telithromycin.Approved
TelmisartanThe serum concentration of Brentuximab vedotin can be increased when it is combined with Telmisartan.Approved, Investigational
TemsirolimusThe serum concentration of Brentuximab vedotin can be increased when it is combined with Temsirolimus.Approved
TerazosinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Terazosin.Approved
TerfenadineThe serum concentration of Brentuximab vedotin can be increased when it is combined with Terfenadine.Approved, Withdrawn
TergurideThe risk or severity of adverse effects can be increased when Terguride is combined with Brentuximab vedotin.Experimental
TesmilifeneThe serum concentration of Brentuximab vedotin can be decreased when it is combined with Tesmilifene.Investigational
TestosteroneThe serum concentration of Brentuximab vedotin can be increased when it is combined with Testosterone.Approved, Investigational
Testosterone cypionateThe serum concentration of Brentuximab vedotin can be increased when it is combined with Testosterone cypionate.Approved
Testosterone enanthateThe serum concentration of Brentuximab vedotin can be increased when it is combined with Testosterone enanthate.Approved
Testosterone undecanoateThe serum concentration of Brentuximab vedotin can be increased when it is combined with Testosterone undecanoate.Approved, Investigational
TG4010The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with TG4010.Investigational
TicagrelorThe serum concentration of Brentuximab vedotin can be increased when it is combined with Ticagrelor.Approved
TiclopidineThe metabolism of Brentuximab vedotin can be decreased when combined with Ticlopidine.Approved
TocilizumabThe serum concentration of Brentuximab vedotin can be decreased when it is combined with Tocilizumab.Approved
TofacitinibBrentuximab vedotin may increase the immunosuppressive activities of Tofacitinib.Approved, Investigational
TolvaptanThe serum concentration of Tolvaptan can be increased when it is combined with Brentuximab vedotin.Approved
TrastuzumabTrastuzumab may increase the cardiotoxic activities of Brentuximab vedotin.Approved, Investigational
TrazodoneThe serum concentration of Brentuximab vedotin can be decreased when it is combined with Trazodone.Approved, Investigational
TrifluoperazineThe serum concentration of Brentuximab vedotin can be increased when it is combined with Trifluoperazine.Approved, Investigational
TriflupromazineThe serum concentration of Brentuximab vedotin can be increased when it is combined with Triflupromazine.Approved, Vet Approved
TrimethoprimThe serum concentration of Brentuximab vedotin can be decreased when it is combined with Trimethoprim.Approved, Vet Approved
TrimipramineThe serum concentration of Brentuximab vedotin can be increased when it is combined with Trimipramine.Approved
TroleandomycinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Troleandomycin.Approved
Varicella Zoster Vaccine (Live/Attenuated)The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Varicella Zoster Vaccine (Live/Attenuated).Approved
VelpatasvirThe serum concentration of Brentuximab vedotin can be increased when it is combined with Velpatasvir.Approved, Investigational
VemurafenibThe serum concentration of Brentuximab vedotin can be decreased when it is combined with Vemurafenib.Approved
VenlafaxineThe serum concentration of Brentuximab vedotin can be increased when it is combined with Venlafaxine.Approved
VerapamilThe serum concentration of Brentuximab vedotin can be decreased when it is combined with Verapamil.Approved
VinblastineThe serum concentration of Brentuximab vedotin can be decreased when it is combined with Vinblastine.Approved
VincristineThe serum concentration of Brentuximab vedotin can be decreased when it is combined with Vincristine.Approved, Investigational
VinorelbineThe serum concentration of Brentuximab vedotin can be increased when it is combined with Vinorelbine.Approved, Investigational
VoriconazoleThe serum concentration of Brentuximab vedotin can be increased when it is combined with Voriconazole.Approved, Investigational
VoxilaprevirThe serum concentration of Brentuximab vedotin can be increased when it is combined with Voxilaprevir.Approved, Investigational
Yellow Fever VaccineThe risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Yellow Fever Vaccine.Approved, Investigational
ZimelidineThe serum concentration of Brentuximab vedotin can be increased when it is combined with Zimelidine.Withdrawn
ZiprasidoneThe metabolism of Brentuximab vedotin can be decreased when combined with Ziprasidone.Approved
Food Interactions
No interactions found.

References

Synthesis Reference

Francisco JA, Cerveny CG, Meyer DL, Mixan BJ, Klussman K, Chace DF, Rejniak SX, Gordon KA, DeBlanc R, Toki BE, Law CL, Doronina SO, Siegall CB, Senter PD, Wahl AF: cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity. Blood. 2003 Aug 15;102(4):1458-65. Epub 2003 Apr 24

General References
  1. Francisco JA, Cerveny CG, Meyer DL, Mixan BJ, Klussman K, Chace DF, Rejniak SX, Gordon KA, DeBlanc R, Toki BE, Law CL, Doronina SO, Siegall CB, Senter PD, Wahl AF: cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity. Blood. 2003 Aug 15;102(4):1458-65. Epub 2003 Apr 24. [PubMed:12714494]
  2. Eichenauer DA, Plutschow A, Kreissl S, Sokler M, Hellmuth JC, Meissner J, Mathas S, Topp MS, Behringer K, Klapper W, Kuhnert G, Dietlein M, Kobe C, Fuchs M, Diehl V, Engert A, Borchmann P: Incorporation of brentuximab vedotin into first-line treatment of advanced classical Hodgkin's lymphoma: final analysis of a phase 2 randomised trial by the German Hodgkin Study Group. Lancet Oncol. 2017 Dec;18(12):1680-1687. doi: 10.1016/S1470-2045(17)30696-4. Epub 2017 Nov 10. [PubMed:29133014]
  3. Cao H, Yamamoto K, Yang LX, Weber R: Brentuximab vedotin: first-line agent for advanced Hodgkin lymphoma. Anticancer Res. 2013 Sep;33(9):3879-85. [PubMed:24023323]
  4. Horie R, Watanabe T: CD30: expression and function in health and disease. Semin Immunol. 1998 Dec;10(6):457-70. doi: 10.1006/smim.1998.0156. [PubMed:9826579]
  5. FDA expands approval of Adcetris for first-line treatment of Stage III or IV classical Hodgkin lymphoma in combination with chemotherapy [Link]
  6. Seattle Genetics Announces FDA Approval of ADCETRIS® (Brentuximab Vedotin) in Combination with Chemotherapy for Adults with Previously Untreated Stage III or IV Classical Hodgkin Lymphoma Read more: http://www.digitaljournal.com/pr/3703005#ixzz5AKAaxmbe [Link]
  7. NCCN Flash UpdatesTM: NCCN Guidelines® and NCCN Compendium® Updated [Link]
  8. EMA label [Link]
  9. Cancer Care Ontario Formulary [Link]
  10. Merck Manuals, Progressive Multifocal Leukoencephalopathy [Link]
  11. Seattle genetics Brentuximab Vedotin [Link]
  12. Brentuximab vedotin: clinical updates and practical guidance [Link]
External Links
KEGG Drug
D09587
PubChem Substance
347910376
ChEMBL
CHEMBL1742994
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Brentuximab_vedotin
ATC Codes
L01XC12 — Brentuximab vedotin
AHFS Codes
  • 10:00.00 — Antineoplastic Agents
FDA label
Download (217 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0Active Not RecruitingTreatmentMalignant Lymphomas1
1Active Not RecruitingTreatmentLeukemia Acute Myeloid Leukemia (AML) / Leukemia, Lymphoblastic, Acute / Myelodysplastic Syndromes1
1Active Not RecruitingTreatmentLymphoma, Hodgkins / Refractory / Relapses1
1Active Not RecruitingTreatmentLymphoma, Large B-Cell, Diffuse (DLBCL)1
1CompletedTreatmentAnaplastic Large-Cell Lymphoma / Lymphoma, Hodgkins1
1CompletedTreatmentCarcinoma NOS / Hodgkins Disease (HD) / Lymphoma, Large-Cell, Anaplastic / Neoplasms / Non-Hodgkin's Lymphoma (NHL)1
1CompletedTreatmentGraft Versus Host Disease (GVHD)1
1CompletedTreatmentHodgkins Disease (HD)1
1CompletedTreatmentHodgkins Disease (HD) / Lymphoma, Large-Cell, Anaplastic / Non-Hodgkin's Lymphoma (NHL)2
1CompletedTreatmentLymphoma, Large-Cell, Anaplastic / Lymphoma, NK-cell / T-Cell Lymphomas1
1CompletedTreatmentRecurrent Adult Hodgkin's Lymphoma1
1Not Yet RecruitingTreatmentCD30-Positive Neoplastic Cells Present / Folliculotropic Mycosis Fungoides / Recurrent Mycosis Fungoides / Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma / Refractory Mycosis Fungoides / Refractory Primary Cutaneous T-Cell Non-Hodgkin Lymphoma / Sezary Syndrome1
1Not Yet RecruitingTreatmentCD30-positive Lymphoma / CD30-positive Solid Tumor1
1Not Yet RecruitingTreatmentLymphoma, Hodgkins / Lymphoma, T-Cell, Cutaneous / Lymphoma, T-Cell, Peripheral1
1RecruitingTreatmentAcute Myelogenous Leukaemia (AML)1
1RecruitingTreatmentCD30-Positive Neoplastic Cells Present / Recurrent Hodgkin Lymphoma / Refractory Hodgkin Lymphoma1
1RecruitingTreatmentClassical Hodgkin Lymphoma / Recurrent Adult Hodgkin's Lymphoma / Recurrent Classical Hodgkin Lymphoma / Recurrent Hodgkin Lymphoma / Refractory Classical Hodgkin Lymphoma / Refractory Hodgkin Lymphoma1
1RecruitingTreatmentCutaneous T-Cell Lymphoma (CTCL)1
1RecruitingTreatmentMycosis Fungoides (MF) / Sézary Syndrome1
1RecruitingTreatmentRecurrent Adult Hodgkin's Lymphoma / Recurrent Childhood Hodgkin Lymphoma / Recurrent Hodgkin Lymphoma / Refractory Hodgkin Lymphoma1
1TerminatedTreatmentGraft Versus Host Disease (GVHD)1
1TerminatedTreatmentHodgkins Disease (HD) / Lymphoma, Large-Cell, Anaplastic / Non-Hodgkin's Lymphoma (NHL)1
1WithdrawnTreatmentAnaplastic Large Cell Lymphoma / CD30+ Peripheral T-cell Lymphoma / Classical Hodgkin Lymphoma / Malignant Neoplasms Stated as Primary Lymphoid Haematopoietic1
1, 2Active Not RecruitingTreatmentAnaplastic Large Cell Lymphoma / Lymphoma, Hodgkins1
1, 2Active Not RecruitingTreatmentCD30 Positive Primary Mediastinal Large B-cell Lymphoma, CD30 Positive Diffuse Large B-cell Lymphoma or CD30 Positive Grey Zone Lymphoma1
1, 2Active Not RecruitingTreatmentClassical Hodgkin Lymphoma1
1, 2Active Not RecruitingTreatmentHodgkins Disease (HD)1
1, 2Active Not RecruitingTreatmentLymphoma, Hodgkins2
1, 2Active Not RecruitingTreatmentRecurrent Adult Hodgkin's Lymphoma / Recurrent Childhood Hodgkin Lymphoma / Refractory Childhood Hodgkin Lymphoma1
1, 2Not Yet RecruitingTreatmentLymphoma, Large B-Cell, Diffuse (DLBCL)1
1, 2RecruitingTreatmentAIDS-Related Hodgkin Lymphoma / Ann Arbor Stage II Hodgkin Lymphoma / Ann Arbor Stage IIA Hodgkin Lymphoma / Ann Arbor Stage IIB Hodgkin Lymphoma / Ann Arbor Stage III Hodgkin Lymphoma / Ann Arbor Stage IIIA Hodgkin Lymphoma / Ann Arbor Stage IIIB Hodgkin Lymphoma / Ann Arbor Stage IV Hodgkin Lymphoma / Ann Arbor Stage IVA Hodgkin Lymphoma / Ann Arbor Stage IVB Hodgkin Lymphoma / CD30-Positive Neoplastic Cells Present / Classical Hodgkin Lymphoma / Human Immunodeficiency Virus (HIV) Infections / Stage II Hodgkin Lymphoma / Stage IIA Hodgkin Lymphoma / Stage IIB Hodgkin Lymphoma / Stage III Hodgkin Lymphoma / Stage IIIA Hodgkin Lymphoma / Stage IIIB Hodgkin Lymphoma / Stage IV Hodgkin Lymphoma / Stage IVA Hodgkin Lymphoma / Stage IVB Hodgkin Lymphoma1
1, 2RecruitingTreatmentALK+ Anaplastic Large Cell Lymphoma1
1, 2RecruitingTreatmentAdult Grade III Lymphomatoid Granulomatosis / Adult Nasal Type Extranodal NK/T-Cell Lymphoma / Anaplastic Large Cell Lymphoma / Angioimmunoblastic T-Cell Lymphoma / Contiguous Stage II Adult Burkitt Lymphoma / Contiguous Stage II Adult Diffuse Large Cell Lymphoma / Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma / Contiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma / Contiguous Stage II Adult Immunoblastic Large Cell Lymphoma / Contiguous Stage II Adult Lymphoblastic Lymphoma / Contiguous Stage II Grade 1 Follicular Lymphoma / Contiguous Stage II Grade 2 Follicular Lymphoma / Contiguous Stage II Grade 3 Follicular Lymphoma / Contiguous Stage II Mantle Cell Lymphoma / Contiguous Stage II Marginal Zone Lymphoma / Contiguous Stage II Small Lymphocytic Lymphoma / Cutaneous B-Cell Non-Hodgkin Lymphoma / Epstein-Barr Virus Infections / Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue / Hepatosplenic T-Cell Lymphoma / Intraocular Lymphoma / Nodal marginal zone B-cell lymphomas / Noncontiguous Stage II Adult Burkitt Lymphoma / Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma / Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma / Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma / Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma / Noncontiguous Stage II Adult Lymphoblastic Lymphoma / Noncontiguous Stage II Grade 1 Follicular Lymphoma / Noncontiguous Stage II Grade 2 Follicular Lymphoma / Noncontiguous Stage II Grade 3 Follicular Lymphoma / Noncontiguous Stage II Mantle Cell Lymphoma / Noncontiguous Stage II Marginal Zone Lymphoma / Noncontiguous Stage II Small Lymphocytic Lymphoma / Noncutaneous Extranodal Lymphoma / Peripheral T-Cell Lymphoma (PTCL) / Post-Transplant Lymphoproliferative Disorder / Progressive Hairy Cell Leukemia, Initial Treatment / Recurrent Adult Burkitt Lymphoma / Recurrent Adult Diffuse Mixed Cell Lymphoma / Recurrent Adult Diffuse Small Cleaved Cell Lymphoma / Recurrent Adult Grade III Lymphomatoid Granulomatosis / Recurrent Adult Hodgkin's Lymphoma / Recurrent Adult Immunoblastic Large Cell Lymphoma / Recurrent Adult Lymphoblastic Lymphoma / Recurrent Adult T-Cell Leukemia/Lymphoma / Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma / Recurrent Grade 1 Follicular Lymphoma / Recurrent Grade 2 Follicular Lymphoma / Recurrent Grade 3 Follicular Lymphoma / Recurrent Mantle Cell Lymphoma / Recurrent Marginal Zone Lymphoma / Recurrent Mycosis Fungoides/Sezary Syndrome / Recurrent Small Lymphocytic Lymphoma / Refractory Hairy Cell Leukemia / Small Intestine Lymphoma / Splenic Marginal Zone Lymphoma / Stage I Adult Burkitt Lymphoma / Stage I Adult Diffuse Large Cell Lymphoma / Stage I Adult Diffuse Mixed Cell Lymphoma / Stage I Adult Diffuse Small Cleaved Cell Lymphoma / Stage I Adult Hodgkin Lymphoma / Stage I Adult Immunoblastic Large Cell Lymphoma / Stage I Adult Lymphoblastic Lymphoma / Stage I Adult T-Cell Leukemia/Lymphoma / Stage I Cutaneous T-cell Non-Hodgkin Lymphoma / Stage I Grade 1 Follicular Lymphoma / Stage I Grade 2 Follicular Lymphoma / Stage I Grade 3 Follicular Lymphoma / Stage I Mantle Cell Lymphoma / Stage I Marginal Zone Lymphoma / Stage I Small Lymphocytic Lymphoma / Stage IA Mycosis Fungoides/Sezary Syndrome / Stage IB Mycosis Fungoides/Sezary Syndrome / Stage II Adult Hodgkin Lymphoma / Stage II Adult T-Cell Leukemia/Lymphoma / Stage II Cutaneous T-cell Non-Hodgkin Lymphoma / Stage IIA Mycosis Fungoides/Sezary Syndrome / Stage IIB Mycosis Fungoides/Sezary Syndrome / Stage III Adult Burkitt Lymphoma / Stage III Adult Diffuse Large Cell Lymphoma / Stage III Adult Diffuse Mixed Cell Lymphoma / Stage III Adult Diffuse Small Cleaved Cell Lymphoma / Stage III Adult Hodgkin Lymphoma / Stage III Adult Immunoblastic Large Cell Lymphoma / Stage III Adult Lymphoblastic Lymphoma / Stage III Adult T-Cell Leukemia/Lymphoma / Stage III Cutaneous T-Cell Non-Hodgkin Lymphoma / Stage III Grade 1 Follicular Lymphoma / Stage III Grade 2 Follicular Lymphoma / Stage III Grade 3 Follicular Lymphoma / Stage III Mantle Cell Lymphoma / Stage III Marginal Zone Lymphoma / Stage III Small Lymphocytic Lymphoma / Stage IIIA Mycosis Fungoides/Sezary Syndrome / Stage IIIB Mycosis Fungoides/Sezary Syndrome / Stage IV Adult Burkitt Lymphoma / Stage IV Adult Diffuse Large Cell Lymphoma / Stage IV Adult Diffuse Mixed Cell Lymphoma / Stage IV Adult Diffuse Small Cleaved Cell Lymphoma / Stage IV Adult Hodgkin Lymphoma / Stage IV Adult Immunoblastic Large Cell Lymphoma / Stage IV Adult Lymphoblastic Lymphoma / Stage IV Adult T-Cell Leukemia/Lymphoma / Stage IV Cutaneous T-Cell Non-Hodgkin Lymphoma / Stage IV Grade 1 Follicular Lymphoma / Stage IV Grade 2 Follicular Lymphoma / Stage IV Grade 3 Follicular Lymphoma / Stage IV Mantle Cell Lymphoma / Stage IV Marginal Zone Lymphoma / Stage IV Small Lymphocytic Lymphoma / Stage IVA Mycosis Fungoides/Sezary Syndrome / Stage IVB Mycosis Fungoides/Sezary Syndrome / T-Cell Large Granular Lymphocyte Leukemia / Testicular Lymphoma / Untreated Hairy Cell Leukemia / Waldenström's Macroglobulinemia (WM)1
1, 2RecruitingTreatmentAnaplastic Large Cell Lymphoma, ALK-Positive / CD30-Positive Neoplastic Cells Present / Systemic Anaplastic Large Cell Lymphoma1
1, 2RecruitingTreatmentClinical Efficacy / Safety1
1, 2RecruitingTreatmentDcSSc / Diffuse Cutaneous Systemic Sclerosis / Scleroderma1
1, 2RecruitingTreatmentHodgkins Disease (HD)2
1, 2RecruitingTreatmentLymphoma, Hodgkins1
1, 2RecruitingTreatmentMalignant Lymphomas1
1, 2RecruitingTreatmentNon-Hodgkin's Disease1
1, 2RecruitingTreatmentRecurrent Adult Hodgkin's Lymphoma / Refractory Hodgkin Lymphoma / TNFRSF8 Positive1
1, 2TerminatedTreatmentLeukemias1
1, 2WithdrawnTreatmentHematopoietic/Lymphoid Cancer1
1, 2WithdrawnTreatmentLymphoma, Hodgkins / Malignant Lymphomas / Non-Hodgkin's Lymphoma (NHL)1
2Active Not RecruitingTreatmentAdult Lymphocyte Depletion Hodgkin Lymphoma / Adult Lymphocyte Predominant Hodgkin Lymphoma / Adult Mixed Cellularity Hodgkin Lymphoma / Adult Nodular Sclerosis Hodgkin Lymphoma / Stage II Adult Hodgkin Lymphoma / Stage III Adult Hodgkin Lymphoma / Stage IV Adult Hodgkin Lymphoma1
2Active Not RecruitingTreatmentAnaplastic Large-Cell Lymphoma / Lymphoma, Hodgkins1
2Active Not RecruitingTreatmentCD-30 Positive Anaplastic Large T-cell Cutaneous Lymphoma / Cutaneous Lymphomas / Haematological disorders / Malignant Lymphomas / Mycosis Fungoides (MF) / Primary Cutaneous Anaplastic Large Cell Lymphoma / Skin Lymphoma1
2Active Not RecruitingTreatmentHIV-associated Hodgkin Lymphoma / Human Immunodeficiency Virus (HIV) Infections / Stage III Adult Hodgkin Lymphoma / Stage IV Adult Hodgkin Lymphoma1
2Active Not RecruitingTreatmentHodgkins Disease (HD)1
2Active Not RecruitingTreatmentHodgkins Disease (HD) / Lymphoma, Large-Cell, Anaplastic1
2Active Not RecruitingTreatmentLymphoma, Hodgkins4
2Active Not RecruitingTreatmentRelapsed or Refractory EBV-and CD30-positive Lymphomas1
2Active Not RecruitingTreatmentSystemic Lupus Erythematosus (SLE)1
2CompletedTreatmentAcute Lymphocytic Leukemia (ALL) / Anemia, Refractory, With Excess of Blasts / Leukemia Acute Myeloid Leukemia (AML) / Tumors, Solid1
2CompletedTreatmentFollicular B-cell Non-Hodgkin's Lymphoma / Refractory Diffuse Large B Cell Lymphoma1
2CompletedTreatmentGerm Cell Cancer1
2CompletedTreatmentHodgkins Disease (HD)1
2CompletedTreatmentHodgkins Disease (HD) / Lymphoma, Large-Cell, Anaplastic / Non-Hodgkin's Lymphoma (NHL)1
2CompletedTreatmentLymphoma, B-Cell / Lymphoma, Large B-Cell, Diffuse (DLBCL) / Non-Hodgkin's Lymphoma (NHL) / T-Cell Lymphomas1
2CompletedTreatmentLymphoma, Hodgkins1
2CompletedTreatmentLymphoma, Large-Cell, Anaplastic / Non-Hodgkin's Lymphoma (NHL)1
2CompletedTreatmentMalignant mast cell neoplasm / Systemic Mastocytosis / Systemic mastocytosis with associated hematological neoplasm1
2CompletedTreatmentPrimary mediastinal large B-cell lymphomas1
2CompletedTreatmentRecurrent Hodgkin Lymphoma / Refractory Hodgkin Lymphoma1
2CompletedTreatmentRelapsed/Refractory Hodgkin's Lymphoma1
2Not Yet RecruitingTreatmentDiffuse Cutaneous Systemic Sclerosis1
2Not Yet RecruitingTreatmentLymphoma, Hodgkins1
2Not Yet RecruitingTreatmentStage I Hodgkin Lymphoma / Stage IA Hodgkin Lymphoma / Stage IB Hodgkin Lymphoma / Stage II Hodgkin Lymphoma / Stage IIA Hodgkin Lymphoma / Stage IIB Hodgkin Lymphoma1
2RecruitingTreatmentAdult Grade III Lymphomatoid Granulomatosis / Adult Nasal Type Extranodal NK/T-Cell Lymphoma / Anaplastic Large Cell Lymphoma / Angioimmunoblastic T-Cell Lymphoma / CD30-Positive Neoplastic Cells Present / Cutaneous B-Cell Non-Hodgkin Lymphoma / Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue / Hepatosplenic T-Cell Lymphoma / Intraocular Lymphoma / Nodal marginal zone B-cell lymphomas / Noncutaneous Extranodal Lymphoma / Peripheral T-Cell Lymphoma (PTCL) / Post-Transplant Lymphoproliferative Disorder / Recurrent Adult Burkitt Lymphoma / Recurrent Adult Diffuse Large Cell Lymphoma / Recurrent Adult Diffuse Mixed Cell Lymphoma / Recurrent Adult Diffuse Small Cleaved Cell Lymphoma / Recurrent Adult Grade III Lymphomatoid Granulomatosis / Recurrent Adult Hodgkin's Lymphoma / Recurrent Adult Immunoblastic Large Cell Lymphoma / Recurrent Adult Lymphoblastic Lymphoma / Recurrent Adult T-Cell Leukemia/Lymphoma / Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma / Recurrent Grade 1 Follicular Lymphoma / Recurrent Grade 2 Follicular Lymphoma / Recurrent Grade 3 Follicular Lymphoma / Recurrent Hodgkin Lymphoma / Recurrent Mantle Cell Lymphoma / Recurrent Marginal Zone Lymphoma / Recurrent Mycosis Fungoides/Sezary Syndrome / Recurrent Non-Hodgkin Lymphoma / Recurrent Small Lymphocytic Lymphoma / Refractory Hairy Cell Leukemia / Refractory Hodgkin Lymphoma / Refractory Non-Hodgkin's lymphoma / Small Intestine Lymphoma / Splenic Marginal Zone Lymphoma / T-Cell Large Granular Lymphocyte Leukemia / Testicular Lymphoma / Waldenström's Macroglobulinemia (WM)1
2RecruitingTreatmentAdult T-Cell Leukemia/Lymphoma / Anaplastic Large Cell Lymphoma, ALK-Negative / Anaplastic Large Cell Lymphoma, ALK-Positive / Angioimmunoblastic T-Cell Lymphoma / CD30-Positive Neoplastic Cells Present / Enteropathy-Associated T-Cell Lymphoma / Hepatosplenic T-Cell Lymphoma / Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma / Peripheral T-Cell Lymphoma, Not Otherwise Specified / Stage III Anaplastic Large Cell Lymphoma / Stage IV Anaplastic Large Cell Lymphoma1
2RecruitingTreatmentAdult T-Cell Leukemia/Lymphoma / Angioimmunoblastic T-Cell Lymphoma / Enteropathy Associated T-cell Lymphoma (EATCL) / Hepato-splenic T-cell Lymphoma / NK T-Cell Lymphoma / T-Cell Lymphomas / Transformed Mycosis Fungoides1
2RecruitingTreatmentAdult T-Cell Leukemia/Lymphoma / Lymphatic Diseases / Malignant Lymphomas1
2RecruitingTreatmentAnaplastic Large Cell Lymphoma, ALK-Positive / Ann Arbor Stage II Childhood Anaplastic Large Cell Lymphoma / Ann Arbor Stage II Noncutaneous Childhood Anaplastic Large Cell Lymphoma / Ann Arbor Stage III Childhood Anaplastic Large Cell Lymphoma / Ann Arbor Stage III Noncutaneous Childhood Anaplastic Large Cell Lymphoma / Ann Arbor Stage IV Childhood Anaplastic Large Cell Lymphoma / Ann Arbor Stage IV Noncutaneous Childhood Anaplastic Large Cell Lymphoma / CD30-Positive Neoplastic Cells Present / Stage II Childhood Anaplastic Large Cell Lymphoma / Stage III Childhood Anaplastic Large Cell Lymphoma / Stage IV Childhood Anaplastic Large Cell Lymphoma1
2RecruitingTreatmentAnn Arbor Stage IB Hodgkin Lymphoma / Ann Arbor Stage II Hodgkin Lymphoma / Ann Arbor Stage IIA Hodgkin Lymphoma / Ann Arbor Stage IIB Hodgkin Lymphoma / Ann Arbor Stage III Hodgkin Lymphoma / Ann Arbor Stage IIIA Hodgkin Lymphoma / Ann Arbor Stage IIIB Hodgkin Lymphoma / Ann Arbor Stage IV Hodgkin Lymphoma / Ann Arbor Stage IVA Hodgkin Lymphoma / Ann Arbor Stage IVB Hodgkin Lymphoma / Classical Hodgkin Lymphoma / Stage IB Hodgkin Lymphoma / Stage II Hodgkin Lymphoma / Stage IIA Hodgkin Lymphoma / Stage IIB Hodgkin Lymphoma / Stage III Hodgkin Lymphoma / Stage IIIA Hodgkin Lymphoma / Stage IIIB Hodgkin Lymphoma / Stage IV Hodgkin Lymphoma / Stage IVA Hodgkin Lymphoma / Stage IVB Hodgkin Lymphoma1
2RecruitingTreatmentClassical Hodgkin Lymphoma / Hematopoietic Cell Transplantation Recipient / Recurrent Hodgkin Lymphoma / Refractory Hodgkin Lymphoma1
2RecruitingTreatmentEmbryonal Carcinoma / Germ Cell Tumors / Neoplasms, Embryonal Germ Cell Tumors / Nonseminomatous Germ Cell Tumor / Testicular Cancer / Testis cancer1
2RecruitingTreatmentEnteropathy Associated T-cell Lymphoma (EATCL)1
2RecruitingTreatmentGerm Cell Tumors1
2RecruitingTreatmentHodgkins Disease (HD)2
2RecruitingTreatmentLung Diseases Due to External Agents / Mesothelioma1
2RecruitingTreatmentLymphatic Diseases2
2RecruitingTreatmentLymphoma, Hodgkins4
2RecruitingTreatmentLymphoma, Large B-Cell, Diffuse (DLBCL)1
2RecruitingTreatmentNon-Hodgkin's Lymphoma (NHL)1
2RecruitingTreatmentPrimary Cutaneous Anaplastic Large Cell Lymphoma / Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma / Recurrent T-Cell Non-Hodgkin Lymphoma / Refractory Primary Cutaneous T-Cell Non-Hodgkin Lymphoma / Stage I Cutaneous T-cell Non-Hodgkin Lymphoma / Stage II Cutaneous T-cell Non-Hodgkin Lymphoma / Stage III Cutaneous T-Cell Non-Hodgkin Lymphoma / Stage IV Cutaneous T-Cell Non-Hodgkin Lymphoma1
2RecruitingTreatmentRecurrent Hodgkin Lymphoma / Refractory Hodgkin Lymphoma1
2RecruitingTreatmentStage II Childhood Hodgkin Lymphoma / Stage III Childhood Hodgkin Lymphoma / Stage IV Childhood Hodgkin Lymphoma1
2TerminatedTreatmentLymphoma, B-Cell / Lymphoma, Large B-Cell, Diffuse (DLBCL)1
2TerminatedTreatmentMalignant Lymphomas1
2Unknown StatusTreatmentLymphoma, Hodgkins1
2WithdrawnSupportive CareGraft Versus Host Disease (GVHD)1
2WithdrawnTreatmentFollicular Lymphoma (FL) / Grey Zone Lymphoma / High Grade B Cell Lymphoma / Lymphoma, Large B-Cell, Diffuse (DLBCL) / Marginal Zone Lymphoma / Mediastinal Large B-cell Lymphoma / Small Lymphocytic Lymphoma (SLL)1
3Active Not RecruitingTreatmentAnaplastic Large-Cell Lymphoma / Lymphoma, Large-Cell, Anaplastic / Non-Hodgkin's Lymphoma (NHL) / T-Cell Lymphomas1
3Active Not RecruitingTreatmentCutaneous T-Cell Lymphoma (CTCL) / Mycosis Fungoides (MF) / Primary Cutaneous Anaplastic Large Cell Lymphoma1
3Active Not RecruitingTreatmentHodgkins Disease (HD)1
3Active Not RecruitingTreatmentLymphoma, Hodgkins1
3RecruitingTreatmentAnn Arbor Stage IIB Hodgkin Lymphoma / Ann Arbor Stage IIIB Hodgkin Lymphoma / Ann Arbor Stage IV Hodgkin Lymphoma / Ann Arbor Stage IVA Hodgkin Lymphoma / Ann Arbor Stage IVB Hodgkin Lymphoma / Childhood Hodgkin Lymphoma / Classical Hodgkin Lymphoma / Stage IIB Hodgkin Lymphoma / Stage IIIB Hodgkin Lymphoma / Stage IV Hodgkin Lymphoma / Stage IVA Hodgkin Lymphoma / Stage IVB Hodgkin Lymphoma1
3RecruitingTreatmentClassical Hodgkin Lymphoma1
3RecruitingTreatmentHodgkins Disease (HD)1
3RecruitingTreatmentLymphoma, Hodgkins1
4Active Not RecruitingTreatmentAnaplastic Large-Cell Lymphoma1
4Active Not RecruitingTreatmentLymphoma, Hodgkins1
Not AvailableActive Not RecruitingTreatmentCutaneous Lymphomas / Cutaneous T Cell Lymphomas (CTCL) / Mycosis Fungoides (MF) / Non-Hodgkin's Lymphoma (NHL) / Sezary Syndrome1
Not AvailableActive Not RecruitingTreatmentHodgkin Lymphoma, Adult1
Not AvailableAvailableNot AvailableHodgkins Disease (HD) / Lymphoma, Large-Cell, Anaplastic / Lymphoma, T-Cell, Cutaneous / Non-Hodgkin's Lymphoma (NHL)1
Not AvailableCompletedNot AvailableRelapsed or Refractory CD30+ Hodgkin's Lymphoma or Anaplastic Large Cell Lymphoma1
Not AvailableNot Yet RecruitingNot AvailableRelapsed or Refractory Hodgkin's Lymphoma1
Not AvailableRecruitingTreatmentLymphoma, Hodgkins1
Not AvailableTerminatedTreatmentPeripheral T-Cell Lymphoma (PTCL)1
Not AvailableWithdrawnTreatmentMalignant Lymphomas1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
Injection, powder, for solutionIntravenous50 mg
Injection, powder, lyophilized, for solutionIntravenous50 mg/10.5mL
Powder, for solutionIntravenous50 mg
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available

Taxonomy

Description
Not Available
Kingdom
Organic Compounds
Super Class
Organic Acids
Class
Carboxylic Acids and Derivatives
Sub Class
Amino Acids, Peptides, and Analogues
Direct Parent
Peptides
Alternative Parents
Not Available
Substituents
Not Available
Molecular Framework
Not Available
External Descriptors
Not Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Binder
General Function
Tumor necrosis factor-activated receptor activity
Specific Function
Receptor for TNFSF8/CD30L. May play a role in the regulation of cellular growth and transformation of activated lymphoblasts. Regulates gene expression through activation of NF-kappa-B.
Gene Name
TNFRSF8
Uniprot ID
P28908
Uniprot Name
Tumor necrosis factor receptor superfamily member 8
Molecular Weight
63746.47 Da
References
  1. Francisco JA, Cerveny CG, Meyer DL, Mixan BJ, Klussman K, Chace DF, Rejniak SX, Gordon KA, DeBlanc R, Toki BE, Law CL, Doronina SO, Siegall CB, Senter PD, Wahl AF: cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity. Blood. 2003 Aug 15;102(4):1458-65. Epub 2003 Apr 24. [PubMed:12714494]
  2. Seattle genetics Brentuximab Vedotin [Link]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
No
Actions
Substrate
Inhibitor
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Cancer Care Ontario Formulary [Link]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Efflux transmembrane transporter activity
Specific Function
Drug efflux transporter present in a number of stem cells that acts as a regulator of cellular differentiation. Able to mediate efflux from cells of the rhodamine dye and of the therapeutic drug do...
Gene Name
ABCB5
Uniprot ID
Q2M3G0
Uniprot Name
ATP-binding cassette sub-family B member 5
Molecular Weight
138639.48 Da
References
  1. Brentuximab vedotin: clinical updates and practical guidance [Link]

Drug created on May 01, 2013 14:50 / Updated on April 22, 2018 23:40